Jenburkt Pharmaceuticals Limited (JENBURPH.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹892.90 (+2.51%) as of
Key statistics
- Market cap
- 3.94B
- P/E (TTM)
- 12.00
- Forward P/E
- 25.61
- EPS (TTM)
- 74.39
- Dividend yield
- 2.38%
- 52-week range
- 852.00 – 1,321.00
- Beta
- 0.39
- Revenue (TTM)
- 1.69B
- Profit margin
- 19.46%
- Volume
- 76.00
About Jenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, and Zydol Suspension brand names. The company also exports its products. It serves large government, semi-government institutions, missionary hospitals, and public sector enterprises. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 801
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.